Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

M. Swain, Sandra; Baselga, José; Kim, Sung‐Bae; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-­Marc; Schneeweiß, Andreas; Heeson, Sarah; Clark, Emma; Ross, Graham; Benyunes, Mark; Cortés, Javier

doi:10.1056/nejmoa1413513

Public

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Published in New England Journal of Medicine • Feb 18, 2015

Authors:

Sandra M. Swain

José Baselga

Sung‐Bae Kim

Abstract

BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel....

Subject

Pertuzumab

Docetaxel

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!